

CURRICULUM VITAE



Informazioni personali

Cognome SANGALETTI Sabina
Nome Sabina
Data di nascita 09/06/1975

Titoli di studio

Data conseguimento 21/11/2008
Titolo conseguito Dottore di ricerca
Descrizione Philosophy Doctor
Titolo della tesi SPARC, a matricellular protein that modulates tumour-host-cell interactions and immune responses
Nome e indirizzo istituzione The Open University-Milton Keynes

Data conseguimento 17/02/2000
Titolo conseguito Laurea specialistica/magistrale
Descrizione Laurea in Scienze Biologiche
Voto conseguito 110/100 cum laude
Titolo della tesi Substrate specificity of the brush border K⁺-leucine symport of Bombyx mori larval midgut, in extreme pH condition.
Classe di laurea 6S-Classe delle lauree specialistiche in Biologia
Nome e indirizzo istituzione Università degli Studi di MILANO - Via Festa del Perdono, 7 - MILANO

Esperienze lavorative

Nome e indirizzo istituzione Fondazione IRCCS Istituto Nazionale dei Tumori - Via Venezian, 1 - Milano
Periodo 01/01/2023 – in corso
Posizione Ricercatore senior
Qualifica Dirigente Biologo
Tipo di attività svolta Responsabile (PI) di diversi progetti di Ricerca finanziati da AIRC, Ministero della Salute ed FRBB (EraperMed JTC2021).

Nome e indirizzo istituzione	Fondazione IRCCS Istituto Nazionale dei Tumori - Via Venezian, 1 - Milano
Periodo	31/12/2019 - 31/12/2020
Posizione	Ricercatore senior
Qualifica	Ricercatore sanitario (Piramide della Ricerca)
Tipo di attività svolta	Responsabile (PI) di diversi progetti di Ricerca finanziati da AIRC, Ministero della Salute ed FRBB (EraperMed JTC2021)
Nome e indirizzo istituzione	Fondazione IRCCS Istituto Nazionale dei Tumori - Via Venezian, 1 - Milano
Periodo	15/04/2013 - 04/08/2019
Posizione	Ricercatore
Qualifica	Collaboratore coordinato continuativo
Tipo di attività svolta	Responsabile (PI) di diversi progetti di Ricerca finanziati da AIRC/Ministero della Salute
Nome e indirizzo istituzione	Fondazione IRCCS Istituto Nazionale dei Tumori - Via Venezian, 1 - Milano
Periodo	15/04/2010 - 14/04/2013
Posizione	Ricercatore
Qualifica	Collaboratore coordinato continuativo
Tipo di attività svolta	Ricercatore PostDoc. Group leader di diversi progetti di ricerca riguardanti SPARC nell' ambito di grants finanziati al dott. Mario P. Colombo.
Nome e indirizzo istituzione	Fondazione IRCCS Istituto Nazionale dei Tumori - Via Venezian, 1 - Milano
Periodo	10/04/2009 - 09/04/2010
Posizione	Borsista post-doc
Tipo di attività svolta	Group leader di progetti di ricerca riguardanti la matrice extracellulare nell' ambito di grants finanziati al dott. Mario P. Colombo.
Nome e indirizzo istituzione	Fondazione IRCCS Istituto Nazionale dei Tumori - Via Venezian, 1 - Milano
Periodo	01/04/2006 - 06/04/2009
Posizione	Borsista
Tipo di attività svolta	PhD student della Open University of London (fino a Novembre 2008) poi Borsista Post Doc
Nome e indirizzo istituzione	Fondazione IRCCS Istituto Nazionale dei Tumori - Via Venezian, 1 - Milano
Periodo	01/01/2003 - 31/12/2005
Posizione	Borsista
Tipo di attività svolta	Assegnatario borsa triennale FIRC. PhD student Open University of London
Nome e indirizzo istituzione	Fondazione IRCCS Istituto Nazionale dei Tumori - Via Venezian, 1 - Milano
Periodo	21/06/2000 - 31/12/2002
Posizione	Borsista

Tipo di attività svolta	Ricercatore borsista, Unità di Immunoterapia e Terapia Genica, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano.
Nome e indirizzo istituzione	Fondazione IRCCS Istituto Nazionale dei Tumori - Via Venezian, 1 - Milano
Periodo	15/03/2000-14/03/2001
Posizione	Tirocinante.
Tipo di attività svolta	Tirocinio Pratico Annuale per l'abilitazione alla professione di Biologo.
Nome e indirizzo istituzione	Università degli Studi di Milano
Periodo	01/09/1998-01/02/2000
Posizione	Tesista
Tipo di attività svolta	Tesi sperimentale presso il Dipartimento di Biochimica-Direttore Prof. Giorgio Hanozet.
Premi e riconoscimenti	
Riconoscimento	Selezione per la partecipazione alla quinta coorte del "Women Leadership Program"-European Innovation Council (EIC) (Aprile 2024)
Premio Assegnato da	EMBO Travel Grants (2015) EUROPEAN MOLECULAR BIOLOGY ORGANIZATION
Premio Assegnato da	Scholar in training Award (2011) AACR
Premio Assegnato da	Premio Giovani Ricercatori Istituto Nazionale dei Tumori (2010) Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Iscrizione a società scientifiche	Membro della Società Italiana di Ematologia Sperimentale Membro dell'American Association for Cancer Research
Responsabilità scientifiche di progetti di ricerca nazionali ed internazionali	
Finanziamenti attivi	
Descrizione	Principal collaborator-Coordinator of Unit 2

Data dal-data al	Nuova acquisizione-6 Aprile 2024
Titolo	IMPATY-AML: Integrating Molecular and digital PATHologyY to track new response biomarkers in high-risk Acute Myeloid Leukemia during treatment
Bando	PNNR M6/C2 2023-Tumori Rari
Ente Finanziatore	Ministero della Salute-PNNR
Descrizione	Principal Investigator
Data dal-data al	01/03/2021-28/02/2027
Titolo	BuonMarrow: BM on chip as smart sensor of lung cancer relapse
Bando	EIC-Pathfinder
Ente finanziatore	European Innovation Council-Pathfinder
Descrizione	Principal Investigator
Data dal-data al	02/01/2024-31/12/2029
Titolo	Bone marrow stroma cell education expand ZEB1+ neutrophils that detect lung cancer early relapse.
Bando	Investigator Grant-IG 2023
Ente finanziatore	Fondazione AIRC per la ricerca sul cancro ETS
Descrizione	Consortium Partner
Data dal-data al	1/05/2022-1/05/2025
Titolo	SYMMETRY
Bando	bando internazionale ERA PerMed JTC 2021
Ente Finanziatore	FRBB Fondazione Regionale per la Ricerca Biomedica
Finanziamenti completati	
Descrizione	Principal Investigator
Data dal-data al	01/01/2019-31/12/2023
	Role of ZEB1 in stroma-and clone-related mechanisms of immunosuppression and aggressiveness in acute myeloid leukemia
Bando	Investigator Grant IG 2018
Ente Finanziatore	AIRC
Descrizione	Group Leader di un progetto di ricerca multidisciplinare
Data dal-data al	01/01/2017-31/12/2019
Titolo	Molecular and phenotypic landscape of high-grade breast cancer (HGBC) tumor microenvironment: characterization and reconversion of the immune suppressive tumor-surrounding stroma and cell compartments
Bando	Bando per la valorizzazione della ricerca Istituzionale
Ente Finanziatore	Fondazione IRCCS Istituto Nazionale dei Tumori
Descrizione	Principal Investigator
Data dal-data al	04/07/2016-04/07/2019
Titolo	“ Neutrophil extracellular traps in leukemia: from triggers of disease progression to vehicle for new vaccines”
Bando	Bando di Ricerca Finalizzata-Giovani Ricercatori 2013

Ente Finanziatore	Ministero della salute
Descrizione	Principal Investigator
Data dal-Data al	01/01/2013-01/01/2016
Titolo	“Regulation of myeloid cells homeostasis by ECM proteins: implication for autoimmunity and myeloid malignancies”.
Bando	My first Grant AIRC
Ente Finanziatore	AIRC
Abilitazione Scientifica Nazionale	
Settore Concorsuale	05/F1 –Biologia Applicata
Durata	0304/208-03/04/2028
Bando D.D.	1532/2016
Settore Concorsuale	06/A2- Patologia Generale e Clinica
Durata	09/04/2018-09/04/2028
Bando D.D.	1532/2016
Settore Concorsuale	06/N1-Scienze delle Professioni Sanitarie e delle Tecnologie Mediche Applicate
Durata	27/03/2018-27/03/2028
Bando D.D.	1532/2016
Trasferimento tecnologico	
Autori	Colombo Mario Paolo; Miotti Silvia, Sangaletti Sabina, Tagliabue Elda
Titolo Brevetto	“Compounds binding to JMJD6 with anti-fibrotic activity”
WO Application	WO2016135338A1
App/Pub number	PCT/EP2016/054177
Data di pubblicazione	01/09/2016
Attribuzione di incarichi di ricerca (fellowship)	
Periodo	01/01/2003-31/12/2005
Descrizione	Assegnazione borsa triennale AIRC-FIRC
Ente Finanziatore	AIRC-FIRC
Altre Esperienze professionali caratterizzate da attività di ricerca	
Periodo	01/03/2001-01/06/2001

Descrizione	<p>Periodo formativo presso il laboratorio di Anatomia Patologica dell'Università di Roma sotto la supervisione della Prof. Antonella Stoppacciaro.</p>
Pubblicazioni	<ol style="list-style-type: none"> 1. Prelaj A, Ganzinelli M, Provenzano L, Mazzeo L, Viscardi G, Metro G, <i>et al.</i> APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research. <i>Clin Lung Cancer</i> 2024;25:190-5 2. Bassani B, Simonetti G, Cancila V, Fiorino A, Ciciarello M, Piva A, <i>et al.</i> ZEB1 shapes AML immunological niches, suppressing CD8 T cell activity while fostering Th17 cell expansion. <i>Cell Rep</i> 2024;43:113794 3. Travelli C, Colombo G, Aliotta M, Fagiani F, Fava N, De Sanctis R, <i>et al.</i> Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) neutralization counteracts T cell immune evasion in breast cancer. <i>J Immunother Cancer</i> 2023;11 4. Prelaj A, Ganzinelli M, Trovo F, Roisman LC, Pedrocchi ALG, Kosta S, <i>et al.</i> The EU-funded I(3)LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy. <i>Clin Lung Cancer</i> 2023;24:381-7 5. Perrone M, Chiodoni C, Lecchi M, Botti L, Bassani B, Piva A, <i>et al.</i> ATF3 Reprograms the Bone Marrow Niche in Response to Early Breast Cancer Transformation. <i>Cancer Res</i> 2023;83:117-29 6. Manglaviti S, Bini M, Apollonio G, Zecca E, Galli G, Sangaletti S, <i>et al.</i> High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors. <i>Lung Cancer</i> 2023;186:107417 7. Hsu CL, Schnabl B. The gut–liver axis and gut microbiota in health and liver disease. <i>Nature Reviews Microbiology</i> 2023 8. Chiodoni C, Sangaletti S, Lecchi M, Ciniselli CM, Cancila V, Tripodi I, <i>et al.</i> A three-gene signature marks the time to locoregional recurrence in luminal-like breast cancer. <i>ESMO Open</i> 2023;8:101590 9. Tripodo C, Bassani B, Jachetti E, Cancila V, Chiodoni C, Portararo P, <i>et al.</i> Neutrophil extracellular traps arm DC vaccination against NPM-mutant myeloproliferation. <i>Elife</i> 2022;11 10. Rizzello C, Cancila V, Sangaletti S, Botti L, Ratti C, Milani M, <i>et al.</i> Intracellular osteopontin protects from autoimmunity-driven lymphoma development inhibiting TLR9-MYD88-STAT3 signaling. <i>Mol Cancer</i> 2022;21:215 11. Perrone M, Chiodoni C, Lecchi M, Botti L, Bassani B, Piva A, <i>et al.</i> ATF3 reprograms the bone marrow niche in response to early breast cancer transformation. <i>Cancer Res</i> 2022 12. Galli G, Corsetto PA, Proto C, Lo Russo G, Ganzinelli M, Rulli E, <i>et al.</i> Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer. <i>Clin Lung Cancer</i> 2022;23:e489-e99 13. Ferrara R, Milani M, Garassino MC, Colombo MP, Sangaletti S. Adenosine Pathway in NSCLC With Molecular Drivers: Can Oncogene Addiction Translate Into Immune Addiction? <i>J Thorac Oncol</i> 2022;17:e35-e8 14. Corradi G, Bassani B, Simonetti G, Sangaletti S, Vadakekolathu J, Fontana MC, <i>et al.</i> Release of IFNγ by Acute Myeloid Leukemia Cells Remodels Bone Marrow Immune Microenvironment by Inducing Regulatory T Cells. <i>Clin Cancer Res</i> 2022;28:3141-55

15. Cordero-Sanchez C, Pessolano E, Riva B, Vismara M, Trivigno SMG, Clemente N, *et al.* CIC-39Na reverses the thrombocytopenia that characterizes tubular aggregate myopathy. *Blood Adv* **2022**;6:4471-84
16. Bellenghi M, Talarico G, Botti L, Puglisi R, Tabolacci C, Portararo P, *et al.* SCD5-dependent inhibition of SPARC secretion hampers metastatic spreading and favors host immunity in a TNBC murine model. *Oncogene* **2022**;41:4055-65
17. Sangaletti S, Ferrara R, Tripodo C, Garassino MC, Colombo MP. Myeloid cell heterogeneity in lung cancer: implication for immunotherapy. *Cancer Immunol Immunother* **2021**;70:2429-38
18. Sangaletti S, Botti L, Gulino A, Lecis D, Bassani B, Portararo P, *et al.* SPARC regulation of PMN clearance protects from pristane-induced lupus and rheumatoid arthritis. *iScience* **2021**;24:102510
19. Perrone M, Talarico G, Chiodoni C, Sangaletti S. Impact of Immune Cell Heterogeneity on HER2+ Breast Cancer Prognosis and Response to Therapy. *Cancers (Basel)* **2021**;13
20. Morello G, Cancila V, La Rosa M, Germano G, Lecis D, Amodio V, *et al.* T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Models. *Cancer Immunol Res* **2021**;9:825-37
21. Lecchi M, Verderio P, Cappelletti V, De Santis F, Paolini B, Monica M, *et al.* A combination of extracellular matrix- and interferon-associated signatures identifies high-grade breast cancers with poor prognosis. *Mol Oncol* **2021**;15:1345-57
22. Jachetti E, Sangaletti S, Chiodoni C, Ferrara R, Colombo MP. Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments. *Cell Immunol* **2021**;362:104301
23. Ferrara R, Naigeon M, Auclin E, Duchemann B, Cassard L, Jouniaux JM, *et al.* Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. *Clin Cancer Res* **2021**;27:492-503
24. Bassani B, Tripodo C, Portararo P, Gulino A, Botti L, Chiodoni C, *et al.* CD40 Activity on Mesenchymal Cells Negatively Regulates OX40L to Maintain Bone Marrow Immune Homeostasis Under Stress Conditions. *Front Immunol* **2021**;12:662048
25. Tripodo C, Zanardi F, Iannelli F, Mazzara S, Vegliante M, Morello G, *et al.* A Spatially Resolved Dark- versus Light-Zone Microenvironment Signature Subdivides Germinal Center-Related Aggressive B Cell Lymphomas. *iScience* **2020**;23:101562
26. Sangaletti S, Iannelli F, Zanardi F, Cancila V, Portararo P, Botti L, *et al.* Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces. *EBioMedicine* **2020**;61:103055
27. Porta C, Consonni FM, Morlacchi S, Sangaletti S, Bleve A, Totaro MG, *et al.* Tumor-Derived Prostaglandin E2 Promotes p50 NF-kappaB-Dependent Differentiation of Monocytic MDSCs. *Cancer Res* **2020**;80:2874-88
28. Colombo G, Clemente N, Zito A, Bracci C, Colombo FS, Sangaletti S, *et al.* Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis. *J Mol Med (Berl)* **2020**;98:595-612
29. Chiodoni C, Cancila V, Renzi TA, Perrone M, Tomirotti AM, Sangaletti S, *et al.* Transcriptional Profiles and Stromal Changes Reveal Bone Marrow Adaptation to Early Breast Cancer in Association with Deregulated Circulating microRNAs. *Cancer Res* **2020**;80:484-98

30. Travelli C, Consonni FM, Sangaletti S, Storto M, Morlacchi S, Grolla AA, *et al.* Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells. *Cancer Res* **2019**;79:1938-51
31. Sangaletti S, Talarico G, Chiodoni C, Cappetti B, Botti L, Portararo P, *et al.* SPARC Is a New Myeloid-Derived Suppressor Cell Marker Licensing Suppressive Activities. *Front Immunol* **2019**;10:1369
32. Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, *et al.* Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. *Clin Cancer Res* **2019**;25:989-99
33. Lecis D, Sangaletti S, Colombo MP, Chiodoni C. Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy. *Cancers (Basel)* **2019**;11
34. De Marchi E, Orioli E, Pegoraro A, Sangaletti S, Portararo P, Curti A, *et al.* The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment. *Oncogene* **2019**;38:3636-50
35. Costanza M, Poliani PL, Portararo P, Cappetti B, Musio S, Pagani F, *et al.* DNA threads released by activated CD4(+) T lymphocytes provide autocrine costimulation. *Proc Natl Acad Sci U S A* **2019**;116:8985-94
36. Cordero-Sanchez C, Riva B, Reano S, Clemente N, Zaggia I, Ruffinatti FA, *et al.* A luminal EF-hand mutation in STIM1 in mice causes the clinical hallmarks of tubular aggregate myopathy. *Dis Model Mech* **2019**;13
37. Castagnoli L, Cancila V, Cordoba-Romero SL, Faraci S, Talarico G, Belmonte B, *et al.* WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer. *Oncogene* **2019**;38:4047-60
38. Jachetti E, Cancila V, Rigoni A, Bongiovanni L, Cappetti B, Belmonte B, *et al.* Cross-Talk between Myeloid-Derived Suppressor Cells and Mast Cells Mediates Tumor-Specific Immunosuppression in Prostate Cancer. *Cancer Immunol Res* **2018**;6:552-65
39. De Santis F, Del Vecchio M, Castagnoli L, De Braud F, Di Cosimo S, Franceschini D, *et al.* Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting. *Cytokine Growth Factor Rev* **2018**;44:1-10
40. Cutrona G, Tripodo C, Matis S, Recchia AG, Massucco C, Fabbi M, *et al.* Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence. *Sci Transl Med* **2018**;10
41. Tripodo C, Burocchi A, Piccaluga PP, Chiodoni C, Portararo P, Cappetti B, *et al.* Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling. *Cancer Res* **2017**;77:3685-99
42. Sangaletti S, Chiodoni C, Tripodo C, Colombo MP. Common extracellular matrix regulation of myeloid cell activity in the bone marrow and tumor microenvironments. *Cancer Immunol Immunother* **2017**;66:1059-67
43. Sangaletti S, Chiodoni C, Tripodo C, Colombo MP. The good and bad of targeting cancer-associated extracellular matrix. *Curr Opin Pharmacol* **2017**;35:75-82
44. Ratti C, Botti L, Cancila V, Galvan S, Torselli I, Garofalo C, *et al.* Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors. *Clin Cancer Res* **2017**;23:5149-61

45. Miotti S, Gulino A, Ferri R, Parenza M, Chronowska A, Lecis D, *et al.* Antibody-mediated blockade of JMJD6 interaction with collagen I exerts antifibrotic and antimetastatic activities. *FASEB J* **2017**;31:5356-70
46. Lecciso M, Ocadlikova D, Sangaletti S, TrabANELLI S, De Marchi E, Orioli E, *et al.* ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells. *Front Immunol* **2017**;8:1918
47. Chiodoni C, Sangaletti S, Colombo MP. Matricellular proteins tune myeloid-derived suppressor cell recruitment and function in breast cancer. *J Leukoc Biol* **2017**;102:287-92
48. Sangaletti S, Tripodo C, Santangelo A, Castioni N, Portararo P, Gulino A, *et al.* Mesenchymal Transition of High-Grade Breast Carcinomas Depends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity. *Cell Rep* **2016**;17:233-48
49. Mauri G, Jachetti E, Comuzzi B, Dugo M, Arioli I, Miotti S, *et al.* Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers. *Oncotarget* **2016**;7:3905-20
50. Vitali C, Bassani C, Chiodoni C, Fellini E, Guarnotta C, Miotti S, *et al.* SOCS2 Controls Proliferation and Stemness of Hematopoietic Cells under Stress Conditions and Its Deregulation Marks Unfavorable Acute Leukemias. *Cancer Res* **2015**;75:2387-99
51. Strauss L, Sangaletti S, Consonni FM, Szebeni G, Morlacchi S, Totaro MG, *et al.* RORC1 Regulates Tumor-Promoting "Emergency" Granulomonocytopoiesis. *Cancer Cell* **2015**;28:253-69
52. Rigoni A, Bongiovanni L, Burocchi A, Sangaletti S, Danelli L, Guarnotta C, *et al.* Mast Cells Infiltrating Inflamed or Transformed Gut Alternatively Sustain Mucosal Healing or Tumor Growth. *Cancer Res* **2015**;75:3760-70
53. Chiodoni C, Sangaletti S, Tripodo C, Colombo MP. The ins and outs of osteopontin. *Oncoimmunology* **2015**;4:e978711
54. Bellenghi M, Puglisi R, Pedini F, De Feo A, Felicetti F, Bottero L, *et al.* SCD5-induced oleic acid production reduces melanoma malignancy by intracellular retention of SPARC and cathepsin B. *J Pathol* **2015**;236:315-25
55. Sangaletti S, Tripodo C, Vitali C, Portararo P, Guarnotta C, Casalini P, *et al.* Defective stromal remodeling and neutrophil extracellular traps in lymphoid tissues favor the transition from autoimmunity to lymphoma. *Cancer Discov* **2014**;4:110-29
56. Sangaletti S, Tripodo C, Sandri S, Torselli I, Vitali C, Ratti C, *et al.* Osteopontin shapes immunosuppression in the metastatic niche. *Cancer Res* **2014**;74:4706-19
57. Sangaletti S, Tripodo C, Portararo P, Dugo M, Vitali C, Botti L, *et al.* Stromal niche communalities underscore the contribution of the matricellular protein SPARC to B-cell development and lymphoid malignancies. *Oncoimmunology* **2014**;3:e28989
58. Franco G, Guarnotta C, Frossi B, Piccaluga PP, Boveri E, Gulino A, *et al.* Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma. *Blood* **2014**;123:1836-49
59. Lecis D, De Cesare M, Perego P, Conti A, Corna E, Drago C, *et al.* Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity. *Cell Death Dis* **2013**;4:e920
60. Tripodo C, Sangaletti S, Guarnotta C, Piccaluga PP, Cacciatore M, Giuliano M, *et al.* Stromal SPARC contributes to the detrimental fibrotic

- changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion. *Blood* **2012**;120:3541-54
61. Swartz MA, Iida N, Roberts EW, Sangaletti S, Wong MH, Yull FE, *et al.* Tumor microenvironment complexity: emerging roles in cancer therapy. *Cancer Res* **2012**;72:2473-80
62. Sangaletti S, Tripodo C, Chiodoni C, Guarnotta C, Cappetti B, Casalini P, *et al.* Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. *Blood* **2012**;120:3007-18
63. Cacciatore M, Guarnotta C, Calvaruso M, Sangaletti S, Florena AM, Franco V, *et al.* Microenvironment-centred dynamics in aggressive B-cell lymphomas. *Adv Hematol* **2012**;2012:138079
64. Tripodo C, Sangaletti S, Piccaluga PP, Prakash S, Franco G, Borrello I, *et al.* The bone marrow stroma in hematological neoplasms--a guilty bystander. *Nat Rev Clin Oncol* **2011**;8:456-66
65. Sangaletti S, Tripodo C, Cappetti B, Casalini P, Chiodoni C, Piconese S, *et al.* SPARC oppositely regulates inflammation and fibrosis in bleomycin-induced lung damage. *Am J Pathol* **2011**;179:3000-10
66. Pittoni P, Tripodo C, Piconese S, Mauri G, Parenza M, Rigoni A, *et al.* Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. *Cancer Res* **2011**;71:5987-97
67. Piconese S, Costanza M, Tripodo C, Sangaletti S, Musio S, Pittoni P, *et al.* The matricellular protein SPARC supports follicular dendritic cell networking toward Th17 responses. *J Autoimmun* **2011**;37:300-10
68. Sangaletti S, Tripodo C, Ratti C, Piconese S, Porcasi R, Salcedo R, *et al.* Oncogene-driven intrinsic inflammation induces leukocyte production of tumor necrosis factor that critically contributes to mammary carcinogenesis. *Cancer Res* **2010**;70:7764-75
69. Guiducci C, Tripodo C, Gong M, Sangaletti S, Colombo MP, Coffman RL, *et al.* Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. *J Exp Med* **2010**;207:2931-42
70. Chiodoni C, Colombo MP, Sangaletti S. Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis. *Cancer Metastasis Rev* **2010**;29:295-307
71. Sangaletti S, Di Carlo E, Gariboldi S, Miotti S, Cappetti B, Parenza M, *et al.* Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. *Cancer Res* **2008**;68:9050-9
72. Sangaletti S, Colombo MP. Matricellular proteins at the crossroad of inflammation and cancer. *Cancer Lett* **2008**;267:245-53
73. Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. *Cancer Res* **2007**;67:11438-46
74. Chiodoni C, Iezzi M, Guiducci C, Sangaletti S, Alessandrini I, Ratti C, *et al.* Triggering CD40 on endothelial cells contributes to tumor growth. *J Exp Med* **2006**;203:2441-50
75. Sangaletti S, Gioiosa L, Guiducci C, Rotta G, Rescigno M, Stoppacciaro A, *et al.* Accelerated dendritic-cell migration and T-cell priming in SPARC-deficient mice. *J Cell Sci* **2005**;118:3685-94
76. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. *Cancer Res* **2005**;65:3437-46

77. Sangaletti S, Stoppacciaro A, Guiducci C, Torrisi MR, Colombo MP. Leukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinoma. *J Exp Med* **2003**;198:1475-85
78. Rotta G, Edwards EW, Sangaletti S, Bennett C, Ronzoni S, Colombo MP, *et al.* Lipopolysaccharide or whole bacteria block the conversion of inflammatory monocytes into dendritic cells in vivo. *J Exp Med* **2003**;198:1253-63
79. Chiodoni C, Stoppacciaro A, Sangaletti S, Gri G, Cappetti B, Koezuka Y, *et al.* Different requirements for alpha-galactosylceramide and recombinant IL-12 antitumor activity in the treatment of C-26 colon carcinoma hepatic metastases. *Eur J Immunol* **2001**;31:3101-10

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 196/03.

Milano, 22 Aprile 2024

